Genetic and Pharmacological Targeting of CSF-1/CSF-1R Inhibits Tumor-Associated Macrophages and Impairs BRAF-Induced Thyroid Cancer Progression

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Ryder, Mabel ^a   Gild, Matti ^a   Hohl, Tobias M ^a   Pamer, Eric ^a   Knauf, Jeff ^a   Ghossein, Ronald ^a   Joyce, Johanna A ^a   Fagin, James A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CHEMOKINE RECEPTOR CCR2; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR 1 RECEPTOR; CYTOKINE RECEPTOR; DIPHTHERIA TOXIN; GW 2580; MONOCYTE CHEMOTACTIC PROTEIN 1; PLX 6134; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL DENSITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG TARGETING; GENE TARGETING; MOUSE; NONHUMAN; PROTEIN EXPRESSION; THYROID PAPILLARY CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION;

ANIMALS; ANISOLES; CARCINOMA; CARCINOMA, PAPILLARY; CELL MOVEMENT; CHEMOKINE CCL2; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MICE; MICE, TRANSGENIC; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIMIDINES; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; RECEPTORS, CCR2; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

MURINAE; MUS;

EID: 84872806275     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054302     Document Type: Article

References (49)

1. Ohno S, Suzuki N, Ohno Y, Inagawa H, Soma G, et al. (2003) Tumor-associated macrophages: foe or accomplice of tumors? Anticancer Res 23: 4395-4409.
2. Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H, et al. (2005) Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep 14: 425-431.
3. Lissbrant IF, Stattin P, Wikstrom P, Damber JE, Egevad L, et al. (2000) Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int J Oncol 17: 445-451.
4. Ryder M, Ghossein RA, Ricarte-Filho JCM, Knauf JA, Fagin JA, (2008) Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocrin Relat Cancer 15: 1069-1074.
5. Steidl C, Lee T, Shah SP, Farinha P, Han G, et al. (2010) Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma. N Engl J Med 362: 875-885.
6. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, et al. (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14: 518-527.
7. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, et al. (2006) Macrophages regulate the angiogenic wwitch in a mouse model of breast cancer. Cancer Res 66: 11238-11246.
8. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, et al. (2011) CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475: 222-225.
9. Hanahan D, (1985) Heritable formation of pancreatic beta-cell tumors in transgenic mice expressing recombinant insulin simian virus-40 oncogene. Nature 315: 115-122.
10. Guy CT, (1992) Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Molecular and cellular biology 12: 954-961.
11. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
12. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, et al. (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88: 5399-5404.
13. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, et al. (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63: 1454-1457.
14. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, et al. (2003) High frequency of BRAF mutations in nevi. Nat Genet 33: 19-20.
15. Sedliarou, Saenko V, Lantsov D, Rogounovitch T, Namba H, et al. (2004) The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. Int J Oncol 25: 1729-1735.
16. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, et al. (2009) Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69: 4885-4893.
17. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, et al. (2008) BRAFV600E Mutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study. J Clin Endocrinol Metab 93: 3943-3949.
18. Wei Q, Fang W, Ye L, Shen L, Zhang X, et al. (2012) Density of Tumor Associated Macrophage Correlates with Lymph Node Metastasis in Papillary Thyroid Carcinoma. Thyroid.
19. Caillou B, Talbot M, Weyemi U, Pioche-Durieu C, Al Ghuzlan A, et al. (2011) Tumor-Associated Macrophages (TAMs) Form an Interconnected Cellular Supportive Network in Anaplastic Thyroid Carcinoma. PLoS ONE 6: e22567.
20. Kornfehl J, Wilfing A, Hermann M, (1994) [Immunohistochemical studies of mononuclear cellular infiltrates of papillary, follicular and anaplastic thyroid cancers]. Laryngorhinootologie 73: 183-188.
21. Franco AT, Malaguarnera R, Refetoff S, Liao XH, Lundsmith E, et al. (2011) Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. PNAS 108: 1615-1620.
22. Charles RP, Iezza G, Amendola E, Dankort D, McMahon M, (2011) Mutationally activated BRAFV600E elicits papillary thyroid cancer in the adult mouse. Cancer Res 71: 3863-3871.
23. Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, et al. (2005) Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 65: 4238-4245.
24. Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, et al. (2011) Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest 121: 4700-4711.
25. Hohl TM, Rivera A, Lipuma L, Gallegos A, Shi C, et al. (2009) Inflammatory monocytes facilitate adaptive CD4 T cell responses during respiratory fungal infection. Cell Host & Microbe 6: 470-481.
26. Marks SC, Lane PW, (1976) Osteopetrosis, a new recessive skeletal mutation on chromosome 12 of the mouse. J Hered 67: 11-18.
27. Cecchini MG, Dominguez MG, Mocci S, Wetterwald A, Felix R, et al. (1994) Role of colony stimulating factor-1 in the establishment and regulation of tissue macrophages during postnatal development of the mouse. Development 120: 1357-1372.
28. Lin EY, Nguyen AV, Russell RG, Pollard JW, (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193: 727-740.
29. Pyonteck SM, Gadea BB, Wang HW, Gocheva V, Hunter KE, et al. (2012) Deficiency of the macrophage growth factor CSF-1 disrupts pancreatic neuroendocrine tumor development. Oncogene 31: 1459-1467.
30. Mesa C Jr, Mirza M, Mitsutake N, Sartor M, Medvedovic M, et al. (2006) Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res 66: 6521-6529.
31. Serbina NV, Pamer EG, (2006) Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol 7: 311-317.
32. Phillips R, Lutz M, Premack B, (2005) Differential signaling mechanisms regulate expression of CC chemokine receptor-2 during monocyte maturation. J Inflamm (London) 2: 14.
33. Serbina NV, Jia T, Hohl TM, Pamer EG, (2008) Monocyte-mediated defense against microbial pathogens. Annu Rev Immunol 26: 421-452.
34. Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, et al. (2011) Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGF[beta] signaling. Oncogene 30: 3153-3162.
35. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A, (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555.
36. Oguma K, Oshima H, Aoki M, Uchio R, Naka K, et al. (2008) Activated macrophages promote Wnt signalling through tumour necrosis factor-[alpha] in gastric tumour cells. EMBO J 27: 1671-1681.
37. Ao M, Franco OE, Park D, Raman D, Williams K, et al. (2007) Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res 67: 4244-4253.
38. Orimo A, Gupta PB, Sgroi DC, renzana-Seisdedos F, Delaunay T, et al. (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348.
39. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, et al. (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449: 557-563.
40. Karlmark KR, Weiskirchen R, Zimmermann HW, Gassler N, Ginhoux F, et al. (2009) Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 50: 261-274.
41. Okuma T, Terasaki Y, Kaikita K, Kobayashi H, Kuziel WA, et al. (2004) C-C chemokine receptor 2 (CCR2) deficiency improves bleomycin-induced pulmonary fibrosis by attenuation of both macrophage infiltration and production of macrophage-derived matrix metalloproteinases. J Pathol 204: 594-604.
42. Kitagawa K, Wada T, Furuichi K, Hashimoto H, Ishiwata Y, et al. (2004) Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am J Pathol 165: 237-246.
43. Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, et al. (2007) CCR2 expression correlates with prostate cancer progression. J Cell Biochem 101: 676-685.
44. Weber KSC, Nelson PJ, Grone HJ, Weber C, (1999) Expression of CCR2 by endothelial Cells: implications for MCP-1 mediated wound injury repair and in vivo inflammatory activation of endothelium. Arterioscler Thromb Vasc Biol 19: 2085-2093.
45. Hanna J, Mussaffi H, Steuer G, Hanna S, Deeb M, et al. (2005) Functional aberrant expression of CCR2 receptor on chronically activated NK cells in patients with TAP-2 deficiency. Blood 106: 3465-3473.
46. Ekert J, Murray L, Das A, Sheng H, Giles-Komar J, et al. (2011) Chemokine (C-C motif) ligand 2 mediates direct and indirect fibrotic responses in human and murine cultured fibrocytes. Fibrogenesis & Tissue Repair 4: 23.
47. Pahler JC, Simon T, Erez N, Chen YY, Murdoch C, et al. (2008) Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia 10: 329-340.
48. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, et al. (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discovery 1: 54-67.
49. Coniglio SJ, Eugenin E, Dobrenis K, Stanley E, West B, et al. (2012) Microglial stimulation of glioblastoma invasion involves EGFR and CSF-1R signaling. Mol Med 18: 519-527.